Highlights Algorae Pharmaceuticals Limited

Equities

1AI

AU0000296022

Delayed Australian S.E. Other stock markets 01:00:29 25/06/2024 BST			5-day change	1st Jan Change
0.011 ^AUD	+10.00%		+10.00%	+10.00%

03-08	Algorae Pharmaceuticals Nears Launch of Drug Discovery Platform	MT
02-28	Algorae Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Algorae Pharmaceuticals Nears Launch of Drug Discovery Platform	03-08	MT
Algorae Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Algorae Pharmaceuticals Secures Agreement with HL Pharma	12-28	MT
Algorae Pharmaceuticals Enters Partnership for Developing Drug Discovery AI Platform	25/10/23	MT
Living Cell Technologies Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23	CI
Rights Issue: 1 new share @ 0.008 AUD for 8 existing shares	22/03/23	FA
Living Cell Technologies Limited Reports Earnings Results for the Half Year Ended December 31, 2022	27/02/23	CI
Living Cell Technologies Limited Completes Stage One of the Planned Use of AI in NTCELL's Manufacture	16/09/22	CI
Living Cell Technologies Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31/08/22	CI
Living Cell Technologies Limited Announces its Choroid Plexus Tissue Shipped to Sydney as NTCELL Research Advances	16/08/22	CI
Living Cell Technologies to Use Artificial Intelligence in Parkinson’s Disease Research	23/05/22	MT
Living Cell Technologies Limited Enters A New Phase in Its Research, with Artificial Intelligence to Be Applied to the Groundbreaking Research to Combat Parkinson's Disease	22/05/22	CI
Living Cell Technologies Enters Research Deal With University of Technology Sydney	30/03/22	MT
Living Cell Technologies Limited Advances Plans for A Third Clinical Trial of NTCELL in Parkinson's Disease, Following the Signing of A Research Agreement with the University of Technology Sydney and the Australian Foundation for Diabetes Research	29/03/22	CI
Living Cell Technologies Limited Reports Earnings Results for the Half Year Ended December 31, 2021	25/02/22	CI
Living Cell Technologies Enters Pig Tissue Services Deal for NTCELL Clinical Trial	24/01/22	MT
Rights Issue: 2 new shares @ 0.008 AUD for 3 existing shares	16/11/21	FA
Living Cell Technologies Receives R&D Tax Credit from New Zealand	09/11/21	MT
Living Cell Technologies Limited Secures Funds for 3rd Trial of NTCELL in Parkinson Disease	18/10/21	CI
Living Cell Technologies Limited Reports Earnings Results for the Full Year Ended June 30, 2021	31/08/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Algorae Pharmaceuticals Limited

Equities

1AI

AU0000296022

Highlights

Filters